OncRef

Clinical Trial: NCT01712490

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:Takeda
Information Provided By:Takeda
Last Update Posted:2026-02-27

Study Overview

Brief Summary

This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin [Adriamycin], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtained with ABVD (doxorubicin [Adriamycin],bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL)

Official Title

A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Conditions

Hodgkin Lymphoma

Intervention / Treatment

  • Drug: brentuximab vedotin
  • Drug: doxorubicin
  • Drug: bleomycin
  • Drug: vinblastine
  • Drug: dacarbazine

Other Study ID Numbers

  • C25003
  • 2011-005450-60
  • U1111-1161-4937
  • 12/LO/1950
  • JapicCTI-142491
  • REec-2013-0114
  • 1025002760
  • C25003CTID
  • 2023-506419-16-00
  • 2023

Start Date (Actual)

2012-11-09

Primary Completion Date (Actual)

2017-04-20

Study Completion Date (Actual)

2026-02-02

Enrollment (Actual)

1334

Study Type

Interventional

Phase

Phase 3